ToolGen (KOSDAQ: 199800; CEO Jong-sang Ryu), a leader in genome editing technology, announced that the United States Patent ...

CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the best gene-editing stocks to buy according to hedge funds. On November 11, ...

Crispr Therapeutics (CRSP) quickly rose 1.3% amid some takeover speculation. Crispr (CRSP) is said to have attracted takeover ...

CRISPR has turned a simple fungus into a fast-growing, meat-like protein source with impressively low environmental impact.

Scientists used CRISPR to disable the NRF2 gene, restoring chemotherapy sensitivity in lung cancer cells and slowing tumor ...

By reactivating a long-lost gene, researchers were able to lower uric acid levels and stop damaging fat accumulation in human ...

India has launched BIRSA 101, the nation’s first indigenous CRISPR-based gene therapy for Sickle Cell Disease, marking a ...

An experimental gene-editing treatment shows promise for permanently lowering levels of cholesterol and triglycerides, ...

In a major step forward for cancer care, researchers at ChristianaCare's Gene Editing Institute have shown that disabling the ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Learn more about whether Aurinia Pharmaceuticals Inc. or CRISPR Therapeutics AG is a better investment based on AAII's A+ ...

Outcomes validate the company’s PTAP platform as a foundation for a rapid, adaptable antiviral modality across animal and ...